Keywords: 0.5q4; 0.5 mg intravitreal aflibercept injection every 4 weeks; 2q4; 2 mg intravitreal aflibercept injection every 4 weeks; 2q8; 2 mg intravitreal aflibercept injection every 8 weeks after 3 initial monthly injections; ANCHOR; Anti-VEGF Antibody for the T
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Impact of Baseline Characteristics on Treatment Response to Intravitreal Aflibercept Injection for Wet Age-Related Macular Degeneration
Keywords: AMD; age-related macular degeneration; ANCHOR; The Anti-Vascular Endothelial Growth Factor (VEGF) Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD; BCVA; best-corrected visual acuity; CATT; The Comparison of Age-Rela
Outcomes of Diabetic Macular Edema Eyes with Limited Early Response in the VISTA and VIVID Studies
Keywords: BCVA; best-corrected visual acuity; CI; confidence interval; CST; central subfield thickness; DME; diabetic macular edema; DRSS; Diabetic Retinopathy Severity Scale; IAI; intravitreal aflibercept injection; LS; least square; NPDR; nonproliferative diabeti
Intravitreal Aflibercept for Diabetic Macular Edema
Keywords: aLOCF; last observation carried forward, including measurements after additional or PRN treatment was given; AMD; age-related macular degeneration; BCVA; best-corrected visual acuity; CST; central subfield thickness; DME; diabetic macular edema; DRSS; Dia
Scheduled versus Pro Re Nata Dosing in the VIEW Trials
Keywords: AMD; age-related macular degeneration; BCVA; best-corrected visual acuity; CRT; central retinal thickness; ETDRS; Early Treatment Diabetic Retinopathy Study; OCT; optical coherence tomography; PRN; pro re nata; Rq4; ranibizumab 0.5 mg every 4 weeks; VA; v
Intravitreal Aflibercept for Diabetic Macular Edema
Keywords: 2q4; 2 mg every 4 weeks; 2q8; 2 mg every 8 weeks after 5 initial monthly doses; AE; adverse event; aLOCF; last observation carried forward, including measurements after rescue treatment was given; BCVA; best-corrected visual acuity; CST; central (optical
Intravitreal Aflibercept Injection for Macular Edema Due to Central Retinal Vein Occlusion
Keywords: BCVA; best-corrected visual acuity; CRT; central retinal thickness; CRUISE; Central Retinal Vein Occlusion Study: Evaluation of Efficacy and Safety; CRVO; central retinal vein occlusion; IAI; intravitreal aflibercept injection; NEI VFQ-25; National Eye In